{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:58:49Z","timestamp":1785211129128,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-10-LABX-53-01"],"award-info":[{"award-number":["ANR-10-LABX-53-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009469","name":"Conseil R\u00e9gional du Centre-Val de Loire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","award":["MAGCOT INCa_16718"],"award-info":[{"award-number":["MAGCOT INCa_16718"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejpb.2026.115009","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:59:10Z","timestamp":1770191950000},"page":"115009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of anti-EGFR targeted magnetic nanoparticles for doxorubicin delivery into triple negative breast cancer cells"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7375-251X","authenticated-orcid":false,"given":"Chlo\u00e9","family":"Lameli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6973-6812","authenticated-orcid":false,"given":"Emilie","family":"Allard-Vannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2868-968X","authenticated-orcid":false,"given":"Ga\u00eblle","family":"Dupeyrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8610-1122","authenticated-orcid":false,"given":"Fanny","family":"Boursin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-0186","authenticated-orcid":false,"given":"Nicolas","family":"Aubrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-0735","authenticated-orcid":false,"given":"Igor","family":"Chourpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katel","family":"Herv\u00e9-Aubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115009_b0005","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/jcm12041524","article-title":"Current treatment landscape for early triple-negative breast cancer (TNBC)","volume":"12","author":"Lee","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejpb.2026.115009_b0010","first-page":"1913","article-title":"Triple-negative breast cancer: is there a treatment on the horizon?","author":"Yao","year":"2016","journal-title":"Oncotarget 8"},{"key":"10.1016\/j.ejpb.2026.115009_b0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/EDBK_159135","article-title":"The evolution of triple-negative breast cancer: from biology to novel therapeutics","author":"Anders","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ejpb.2026.115009_b0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12032-011-9827-x","article-title":"EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray","volume":"29","author":"Liu","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejpb.2026.115009_b0025","first-page":"3","article-title":"Challenges in the treatment of triple negative and HER2-overexpressing breast cancer","volume":"1","author":"Hoeferlin","year":"2013","journal-title":"J. Surg. Sci."},{"key":"10.1016\/j.ejpb.2026.115009_b0030","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115009_b0035","doi-asserted-by":"crossref","first-page":"12386","DOI":"10.1038\/s41598-024-62991-3","article-title":"Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2026.115009_b0040","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.ajpath.2017.05.018","article-title":"Triple-negative breast cancer: next-generation sequencing for target identification","volume":"187","author":"Marotti","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejpb.2026.115009_b0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2016.12.010","article-title":"Targeting epidermal growth factor receptor in triple negative breast cancer: new discoveries and practical insights for drug development","volume":"53","author":"Costa","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejpb.2026.115009_b0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13058-024-01799-5","article-title":"Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin\/OKI-179 to promote apoptosis","volume":"26","author":"Smoots","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejpb.2026.115009_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125134","article-title":"Enhancing chemo-immunotherapy in triple-negative breast cancer: Co-delivery of doxorubicin and berberine using nanoparticles to downregulate PD-L1 and eliminate cancer stem cells","volume":"670","author":"Shi","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115009_b0060","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00432-022-04189-6","article-title":"Triple negative breast cancer: approved treatment options and their mechanisms of action","volume":"149","author":"Mandapati","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2026.115009_b0065","first-page":"1","article-title":"A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging, Npj","volume":"10","author":"Linders","year":"2024","journal-title":"Aging"},{"key":"10.1016\/j.ejpb.2026.115009_b0070","article-title":"Cardio-oncology\u2019s modern approaches to prevent doxorubicin-induced cardiotoxicity: a systematic review","volume":"16","author":"Palvia","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejpb.2026.115009_b0075","article-title":"A comprehensive review on advances in nanoparticle-mediated cancer therapeutics: current research and future perspectives","author":"Deivayanai","year":"2024","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.ejpb.2026.115009_b0080","first-page":"1","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejpb.2026.115009_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1271420","article-title":"Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer","volume":"11","author":"Zeng","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejpb.2026.115009_b0090","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/molecules29173994","article-title":"Overcoming cancer drug resistance with nanoparticle strategies for key protein inhibition","volume":"29","author":"Yoo","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2026.115009_b0095","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/jpm11080771","article-title":"The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application","volume":"11","author":"Wu","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.ejpb.2026.115009_b0100","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","article-title":"Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?","volume":"27","author":"Nakamura","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2026.115009_b0105","article-title":"Doxil\u00ae \u2013 the first FDA-approved nano-drug: from Basics via CMC","author":"(Chezy) Barenholz","year":"2016","journal-title":"Cell Culture and Animal Studies to Clinical Use"},{"key":"10.1016\/j.ejpb.2026.115009_b0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2015.10.058","article-title":"Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics","volume":"496","author":"Kandasamy","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115009_b0115","doi-asserted-by":"crossref","DOI":"10.1142\/S1793292022300079","article-title":"Iron oxide nanoparticles (IONPs): synthesis, surface functionalization, and targeting drug delivery strategies: mini-review","volume":"17","author":"Abdulwahid","year":"2022","journal-title":"Nano"},{"key":"10.1016\/j.ejpb.2026.115009_b0120","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/gutjnl-2016-311393","article-title":"Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer","volume":"65","author":"Mahajan","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ejpb.2026.115009_b0125","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/IJN.S155537","article-title":"Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy","volume":"13","author":"Yang","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejpb.2026.115009_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1416737","article-title":"Dual conjugation of magnetic nanoparticles with antibodies and siRNA for cell-specific gene silencing in vascular cells","volume":"4","author":"Karpinska","year":"2024","journal-title":"Front. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115009_b0135","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/pharmaceutics15010236","article-title":"Superparamagnetic iron oxide nanoparticles (SPION): from fundamentals to state-of-the-art innovative applications for cancer therapy","volume":"15","author":"Vangijzegem","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115009_b0140","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1039\/D1BM01963E","article-title":"Superparamagnetic iron oxide nanoparticles for magnetic hyperthermia: recent advancements, molecular effects, and future directions in the omics era","volume":"10","author":"Pucci","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejpb.2026.115009_b0145","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1039\/D4MA01120A","article-title":"Enhancing the magnetic properties of superparamagnetic iron oxide nanoparticles using hydrothermal treatment for magnetic hyperthermia application","volume":"6","author":"Martins","year":"2025","journal-title":"Mater. Adv."},{"key":"10.1016\/j.ejpb.2026.115009_b0150","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.exphem.2008.01.012","article-title":"Marrow cell therapies for cardiovascular diseases","volume":"36","author":"Cogle","year":"2008","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejpb.2026.115009_b0155","first-page":"35","article-title":"Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application","volume":"1","author":"Wang","year":"2011","journal-title":"Quant. Imaging Med. Surg."},{"key":"10.1016\/j.ejpb.2026.115009_b0160","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.3390\/cancers14215269","article-title":"Quantifying liver heterogeneity via R2*-MRI with super-paramagnetic iron oxide nanoparticles (SPION) to characterize liver function and tumor","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejpb.2026.115009_b0165","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/ma12040617","article-title":"Superparamagnetic iron oxide nanoparticles\u2014current and prospective medical applications","volume":"12","author":"Duli\u0144ska-Litewka","year":"2019","journal-title":"Materials"},{"key":"10.1016\/j.ejpb.2026.115009_b0170","doi-asserted-by":"crossref","first-page":"986","DOI":"10.7150\/thno.4827","article-title":"Multifunctional iron oxide nanoparticles for diagnostics, therapy and macromolecule delivery","volume":"3","author":"Yen","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2026.115009_b0175","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejpb.2020.10.004","article-title":"Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells","volume":"157","author":"Nguyen","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115009_b0180","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.07.006","article-title":"Novel method of doxorubicin\u2013SPION reversible association for magnetic drug targeting","volume":"363","author":"Munnier","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115009_b0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2011.06.010","article-title":"A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting","volume":"423","author":"Gautier","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115009_b0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1021\/acsmedchemlett.4c00480","article-title":"A conjugate of an EGFR-binding peptide and doxorubicin shows selective toxicity to triple-negative breast cancer cells","volume":"16","author":"Than","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejpb.2026.115009_b0195","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1038\/s41598-023-30950-z","article-title":"A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer","volume":"13","author":"Mamot","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2026.115009_b0200","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/PAS.0b013e31819c1c93","article-title":"Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers","volume":"33","author":"Collins","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ejpb.2026.115009_b0205","first-page":"1361","article-title":"Immunohistochemical profile and morphology in triple - negative breast cancers","volume":"7","author":"Rao","year":"2013","journal-title":"J. Clin. Diagn. Res. JCDR"},{"key":"10.1016\/j.ejpb.2026.115009_b0210","doi-asserted-by":"crossref","unstructured":"Y. Si, Y. Zhang, H.G. Ngo, J.-S. Guan, K. Chen, Q. Wang, A.P. Singh, Y. Xu, L. Zhou, E.S. Yang, X. (Margaret) Liu, Targeted liposomal chemotherapies to treat triple-negative breast cancer, Cancers 13 (2021) 3749. 10.3390\/cancers13153749.","DOI":"10.3390\/cancers13153749"},{"key":"10.1016\/j.ejpb.2026.115009_b0215","doi-asserted-by":"crossref","first-page":"324","DOI":"10.7150\/jca.2.324","article-title":"Targeting EGFR in triple negative breast cancer","volume":"2","author":"Ueno","year":"2011","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejpb.2026.115009_b0220","article-title":"Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer","volume":"73618\u201373637","author":"Guerrab","year":"2016","journal-title":"Oncotarget 7"},{"key":"10.1016\/j.ejpb.2026.115009_b0225","first-page":"1609","article-title":"A perspective on anti-EGFR therapies targeting triple-negative breast cancer","volume":"6","author":"Nakai","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejpb.2026.115009_b0230","doi-asserted-by":"crossref","first-page":"37099","DOI":"10.1039\/C6RA06076E","article-title":"Covalent conjugation of cysteine-engineered scFv to PEGylated magnetic nanoprobes for immunotargeting of breast cancer cells","volume":"6","author":"Alric","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2026.115009_b0235","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12951-018-0341-6","article-title":"Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes","volume":"16","author":"Alric","year":"2018","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.ejpb.2026.115009_b0240","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12951-020-00723-1","article-title":"Superparamagnetic iron oxide nanoparticles conjugated with A\u03b2 oligomer-specific scFv antibody and class a scavenger receptor activator show therapeutic potentials for Alzheimer\u2019s Disease","volume":"18","author":"Liu","year":"2020","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.ejpb.2026.115009_b0245","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.biomaterials.2009.10.036","article-title":"Nanoparticles functionalised with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells","volume":"31","author":"Vigor","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2026.115009_b0250","first-page":"3781","article-title":"Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer","volume":"8","author":"Chen","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejpb.2026.115009_b0255","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/19\/46\/465608","article-title":"The development of stable aqueous suspensions of PEGylated SPIONs for biomedical applications","volume":"19","author":"Herv\u00e9","year":"2008","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejpb.2026.115009_b0260","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcis.2017.03.106","article-title":"Synthesis and in vitro evaluation of fluorescent and magnetic nanoparticles functionalized with a cell penetrating peptide for cancer theranosis","volume":"499","author":"Perillo","year":"2017","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2026.115009_b0265","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ijpharm.2017.05.022","article-title":"Stealth magnetic nanocarriers of siRNA as platform for breast cancer theranostics","volume":"532","author":"Bruniaux","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115009_b0270","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1021\/j100214a025","article-title":"Adsorption and surface-enhanced Raman of dyes on silver and gold sols","volume":"86","author":"Lee","year":"1982","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.ejpb.2026.115009_b0275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chemphyslip.2005.02.003","article-title":"Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer","volume":"135","author":"Garbuzenko","year":"2005","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.ejpb.2026.115009_b0280","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1021\/acs.nanolett.0c03756","article-title":"Brush conformation of polyethylene glycol determines the stealth effect of nanocarriers in the low protein adsorption regime","volume":"21","author":"Li","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejpb.2026.115009_b0285","doi-asserted-by":"crossref","first-page":"10748","DOI":"10.1039\/D1NR02065J","article-title":"Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery","volume":"13","author":"Shi","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2026.115009_b0290","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.3390\/pharmaceutics14122679","article-title":"Radiolabeling, quality control and in vivo imaging of multimodal targeted nanomedicines","volume":"14","author":"Nguyen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115009_b0295","doi-asserted-by":"crossref","first-page":"7354","DOI":"10.1039\/c3an00787a","article-title":"SERS spectroscopic approach to study doxorubicin complexes with Fe2+ ions and drug release from SPION-based nanocarriers","volume":"138","author":"Gautier","year":"2013","journal-title":"Analyst"},{"key":"10.1016\/j.ejpb.2026.115009_b0300","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2174\/1567201813666151228104643","article-title":"Liposomal Doxorubicin delivery systems: effects of formulation and processing parameters on drug loading and release behavior","volume":"13","author":"Mohammadi","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115009_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e01955","article-title":"Doxorubicin loaded carboxymethyl Assam bora rice starch coated superparamagnetic iron oxide nanoparticles as potential antitumor cargo","volume":"5","author":"Mohapatra","year":"2019","journal-title":"Heliyon"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:42:37Z","timestamp":1777592557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126000305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":61,"alternative-id":["S0939641126000305"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115009","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of anti-EGFR targeted magnetic nanoparticles for doxorubicin delivery into triple negative breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115009"}}